Leucovorin and Fluorouracil Compared With Observation in Treating Patients With Colorectal Cancer That Has Been Surgically Removed - Full Text View

Sponsored by:	Institute of Cancer Research, United Kingdom
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00005586

Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether chemotherapy is more effective than observation in patients who have had surgery to remove colorectal cancer.

PURPOSE: This randomized phase III trial is studying leucovorin and fluorouracil to see how well they work compared to observation in treating patients with colorectal cancer that has been surgically removed.

Condition	Intervention	Phase
Colorectal Cancer	Drug: L-leucovorin Drug: fluorouracil Procedure: adjuvant therapy	Phase III

MedlinePlus related topics: Cancer Colorectal Cancer Surgery

Drug Information available for: Fluorouracil Leucovorin Citrovorum factor Leucovorin Calcium Folinic acid calcium salt pentahydrate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control
Official Title:	A UKCCCR Study of Adjuvant Chemotherapy for Colorectal Cancer

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

All-cause mortality [ Designated as safety issue: No ]

Secondary Outcome Measures:

Death from colorectal cancer [ Designated as safety issue: No ]
Disease recurrence [ Designated as safety issue: No ]

Estimated Enrollment:	2500
Study Start Date:	October 1997

Detailed Description:

OBJECTIVES:

Compare all-cause mortality in patients with resected colorectal cancer treated with adjuvant chemotherapy with L-leucovorin and fluorouracil vs observation.
Compare the recurrence rates in patients treated with this regimen vs observation.
Compare the effectiveness of a monthly 5-day schedule vs a once weekly schedule of L-leucovorin and fluorouracil in this patient population.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to receive adjuvant chemotherapy (arm I) or undergo observation only (arm II).

Arm I: Within 12 weeks of surgery, patients receive L-leucovorin IV followed by fluorouracil IV on days 1-5 every 4 weeks for 6 courses.

Alternatively, patients may receive L-leucovorin IV followed by fluorouracil IV on day 1 weekly for 30 weeks.

Arm II: Patients undergo observation. Patients are followed annually.

PROJECTED ACCRUAL: A total of 2,500 patients (1,250 per arm) will be accrued for this study.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Completely resected stage II or III colorectal cancer
No distant metastases
No positive resection margins
No positive peritoneal washings

PATIENT CHARACTERISTICS:

Age:

18 and over

Performance status:

Not specified

Life expectancy:

Not specified

Hematopoietic:

Not specified

Hepatic:

Not specified

Renal:

Not specified

Other:

No clear definite indication for, or contraindication against, systemic chemotherapy with L-leucovorin and fluorouracil

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

No concurrent chemotherapy in observation only arm

Endocrine therapy:

Not specified

Radiotherapy:

Concurrent radiotherapy allowed in adjuvant chemotherapy arm provided chemotherapy administered on the once weekly schedule

Surgery:

See Disease Characteristics

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00005586

Locations

United Kingdom, England
Royal London Hospital
London, England, United Kingdom, E1 1BB

Sponsors and Collaborators

Institute of Cancer Research, United Kingdom

Investigators

Study Chair:

Norman Williams, MD

Royal London Hospital

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Publications:

Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007 Dec 15;370(9604):2020-9.

Study ID Numbers:	CDR0000067660, NCRI-QUASAR1, EU-99053, UKCCCR-QUASAR1, ISRCTN82375386
Study First Received:	May 2, 2000
Last Updated:	February 6, 2009
ClinicalTrials.gov Identifier:	NCT00005586 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

stage II colon cancer
stage III colon cancer
stage II rectal cancer
stage III rectal cancer

Study placed in the following topic categories:

Antimetabolites
Vitamin B Complex
Digestive System Neoplasms
Immunologic Factors
Rectal Neoplasms
Gastrointestinal Diseases
Colonic Diseases
Adjuvants, Immunologic
Rectal Neoplasm
Leucovorin
Trace Elements

Intestinal Diseases
Immunosuppressive Agents
Rectal Diseases
Intestinal Neoplasms
Digestive System Diseases
Rectal Cancer
Vitamins
Fluorouracil
Gastrointestinal Neoplasms
Micronutrients
Colorectal Neoplasms

Additional relevant MeSH terms:

Antimetabolites
Antimetabolites, Antineoplastic
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Diseases
Antineoplastic Agents
Colonic Diseases
Physiological Effects of Drugs
Leucovorin
Rectal Diseases
Neoplasms by Site
Therapeutic Uses
Vitamins
Micronutrients

Digestive System Neoplasms
Vitamin B Complex
Growth Substances
Adjuvants, Immunologic
Intestinal Diseases
Immunosuppressive Agents
Intestinal Neoplasms
Pharmacologic Actions
Neoplasms
Digestive System Diseases
Fluorouracil
Gastrointestinal Neoplasms
Colorectal Neoplasms

ClinicalTrials.gov processed this record on May 07, 2009